Eliezer Mendel Van Allen, M.D.
Co-Author
This page shows the publications co-authored by Eliezer Van Allen and Christopher Sweeney.
Connection Strength
0.951
-
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol. 2021 09; 32(9):1157-1166.
Score: 0.235
-
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019 07; 76(1):89-97.
Score: 0.198
-
Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118.
Score: 0.172
-
Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clin Cancer Res. 2016 05 01; 22(9):2183-9.
Score: 0.160
-
FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nat Protoc. 2020 08; 15(8):2503-2518.
Score: 0.055
-
Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol. 2019 Apr 01; 5(4):514-522.
Score: 0.051
-
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
Score: 0.041
-
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8.
Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.